Staar Surgical
This article was originally published in The Gray Sheet
Executive Summary
Ophthalmic products company is evaluating a cash offer to acquire 51-100% of its outstanding common stock at $15 per share from an unnamed entity "whose principals have not been disclosed," the firm reports in a June 28 release. Monrovia, California-based Staar makes minimally invasive devices for refractive, cataract and glaucoma surgery including foldable intraocular lenses
You may also be interested in...
Staar Surgical
Plans to repurchase up to 1 mil. shares of common stock in the open market. The maker of devices used in the refractive, cataract and glaucoma surgery markets recently rejected a cash offer to have 51-100% of its outstanding common stock acquired by an unnamed party at $15 per share (1"The Gray Sheet" July 5, p. 27). The offer was "inadequate" and "not in the best interest" of shareholders, Staar concluded. Staar stock has recently traded in the $15 range, reaching a 52-week high of 17-1/8. The Monrovia, California firm reported second quarter (ended July 2) revenues of $14.7 mil. (up 5%). Net income was $677,000 versus $1.5 mil. for the comparable quarter last year
Staar Surgical
Plans to repurchase up to 1 mil. shares of common stock in the open market. The maker of devices used in the refractive, cataract and glaucoma surgery markets recently rejected a cash offer to have 51-100% of its outstanding common stock acquired by an unnamed party at $15 per share (1"The Gray Sheet" July 5, p. 27). The offer was "inadequate" and "not in the best interest" of shareholders, Staar concluded. Staar stock has recently traded in the $15 range, reaching a 52-week high of 17-1/8. The Monrovia, California firm reported second quarter (ended July 2) revenues of $14.7 mil. (up 5%). Net income was $677,000 versus $1.5 mil. for the comparable quarter last year
Staar Ramping Up Staarvisc Production Following FDA Approval
Staar Surgical's U.S. launch of Staarvisc viscoelastic solution will follow production ramp-up occurring over the next few months, the firm said following receipt of FDA approval July 7.